Close
CDMO Safety Testing 2026
Novotech

Thermo Fisher Partners with X-ELIO for Renewable Energy

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

CordenPharma Seals AmbioPharm Deal to Expand Global Network

CordenPharma, a global contract development and manufacturing organization specializing...

Shilpa Biologicals Urges Stronger CDMO Selection Strategy

Ahead of BIO San Diego next month, Shilpa Biologicals...

Chemspec Europe 2026 Draws Global Industry Participation

Chemspec Europe returned to Cologne on 6โ€“7 May 2026,...
- Advertisement -

Thermo Fisher Scientific has taken a significant step toward achieving its sustainability goals by signing a 10-year virtual power purchase agreement (VPPA) with renewable energy developer X-ELIO. This agreement supports the Lorca solar project, which is set to become operational in 2026 and aims to increase access to renewable electricity for Thermo Fisher and its partners in the pharmaceutical and healthcare industries.

The companyโ€™s 73 MW share of the Lorca solar project, combined with the Serbal solar project announced in 2023, will enable Thermo Fisher to power all of its addressable European sites with 100% renewable electricity. The Lorca project will produce approximately 150,000 megawatt-hours of renewable electricity annually, equivalent to powering around 40,500 European homes for one year.

This achievement accelerates Thermo Fisherโ€™s progress toward its global sustainability target of achieving 80% renewable electricity by 2030, as part of its comprehensive net-zero emissions strategy.

โ€œWhen we collaborate with our customers and suppliers, we accelerate our collective progress toward net-zero emissions,โ€ said Konrad Bauer, senior vice president, global business services, Thermo Fisher Scientific. โ€œAchieving 100 percent renewable electricity for our European sites is a significant milestone on our journey, and as cohort lead for this agreement facilitated by the Energize initiative, we are committed to leveraging our experience and insights to help enable similar milestones for our partners.โ€

Driving Decarbonization Across the Supply Chain

The Lorca solar project was developed through collaboration with a cohort of Thermo Fisherโ€™s value chain partnersโ€”GSK, Gilead Sciences, and Haleonโ€”under the Energize initiative. This program, managed by Schneider Electric and the Pharmaceutical Supply Chain Initiative, connects pharmaceutical companies and their suppliers to renewable energy solutions.

As part of this agreement:

  • The project will reduce Scope 2 emissions (from purchased electricity powering company facilities) and Scope 3 emissions (from value chain partners).
  • Thermo Fisher will serve as the cohort lead, leveraging its expertise to foster renewable energy adoption strategies across the healthcare sector.

โ€œMaking the most out of our energy and resources is crucial as we collectively move toward more sustainable solutions across industries and around the world,โ€ said John Powers, vice president, global renewables at Schneider Electric. โ€œThe Energize program aims to drive supply chain decarbonization across the pharmaceutical and healthcare industries while serving as a playbook for other sectors as they look to power their operations with renewable energy.โ€

A Commitment to Net-Zero by 2050

Thermo Fisher continues to lead global sustainability efforts through its commitment to reduce Scope 1 and 2 emissions by 50% by 2030 (based on 2018 levels) and power all of its U.S. sites with renewable electricity by 2026.

By participating in the Lorca project, Thermo Fisher reinforces its alignment with the Sustainable Markets Initiative Health Systems Task Force joint supplier standards and continues to drive innovation in addressing climate challenges across the healthcare and pharmaceutical industries.

The companyโ€™s leadership in renewable energy adoption serves as a blueprint for other sectors seeking to accelerate progress toward a more sustainable future.

 

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

CordenPharma Seals AmbioPharm Deal to Expand Global Network

CordenPharma, a global contract development and manufacturing organization specializing...

Shilpa Biologicals Urges Stronger CDMO Selection Strategy

Ahead of BIO San Diego next month, Shilpa Biologicals...

Chemspec Europe 2026 Draws Global Industry Participation

Chemspec Europe returned to Cologne on 6โ€“7 May 2026,...

Advanced Color Measurement Strengthening Pharma QC

Achieving absolute precision in pharmaceutical manufacturing necessitates a comprehensive and rigorous oversight of physical attributes, with color serving as a primary indicator of chemical stability and composition. By integrating sophisticated instrumentation into the laboratory environment, manufacturers can transition from subjective visual assessments to standardized, data-driven methodologies that satisfy the most stringent global regulatory requirements. This strategic focus on color measurement pharma QC facilitates the early identification of raw material impurities and ensures uncompromising batch-to-batch consistency in final dosage forms, thereby bolstering patient safety and brand reputation.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป